Q-omics provides the consensus-scored TMEM183B profile across patient tissues and cancer cell-line models. TMEM183B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM183B is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, TMEM183B RNA expression shows 16,622 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where TMEM183B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM183B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM183B survival associations across molecular data types. TMEM183B RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM183B RNA expression–survival associations across cancer types. High TMEM183B expression shows unfavorable associations in ACC, LGG, LIHC, UCS and MESO, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM183B RNA expression.
This table summarizes TMEM183B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM183B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM183B shows lower tumor expression in THCA and higher tumor expression in LIHC, COAD, HNSC, KIRC and BLCA. The LIHC box plot shows higher TMEM183B RNA expression in tumor versus normal tissue (log2 FC = +0.336, t-test p < 0.001).
This table shows molecular features associated with TMEM183B in patient tissues and cancer cell lines. In patient samples, TMEM183B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
